Bayer consensus stays cautious, shares trade in the lower DAX range
24.06.2026 - 08:19:13 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 08:15.
Bayer (DE000BAY0017) remains a challenged heavyweight in the DAX. The analyst consensus on the pharmaceutical and crop-science group is cautious, with several major houses keeping neutral ratings and trimmed price targets in recent months, according to MarketScreener and Refinitiv data.
What analysts are signaling
On MarketScreener, around 30 analysts cover Bayer, with a distribution tilted toward Hold recommendations and only a minority on Buy, reflecting a muted stance after the stock's prolonged underperformance versus the DAX benchmark.MarketScreener consensus overview Several investment banks, including UBS and JPMorgan, have in past updates highlighted litigation risks in the United States and high debt following the Monsanto acquisition as key valuation constraints.
Recent analyst notes summarized by Finanznachrichten show that while some houses still see upside from current levels, target prices have gradually been reduced, aligning closer to where the shares trade and signalling less conviction on a rapid recovery.Finanznachrichten Bayer analyst news The average 12-month target, per these aggregators, remains above the market price but the gap has narrowed compared with previous years.
Position in the DAX and peers
On Xetra, Bayer shares recently changed hands in the high-30-euro range, leaving the stock in the lower third of the DAX by one-year performance compared with peers such as Merck KGaA and Sanofi in the broader European pharma space.Boerse Frankfurt price data for Bayer Over the past twelve months the shares have traded well below their pre-2018 levels, underscoring the market's continued discount for litigation and restructuring uncertainty.
Finanzen.net lists Bayer with a market capitalization in the mid tens of billions of euros, materially smaller than global pharma leaders such as Pfizer or Novartis, despite a broad portfolio in pharmaceuticals, consumer health and crop science.Finanzen.net profile and key figures This relative size shift versus peers has emerged gradually over recent years as the share price lagged.
All news and analysis on the Bayer shares
Price data, ad-hoc releases and further analyst commentary on the Bayer shares are bundled on the dedicated topic page and in the company's investor-relations section.
The businesses behind Bayer
Bayer generates revenue in three main divisions: Pharmaceuticals, Consumer Health and Crop Science, with well-known prescription drugs, over-the-counter brands such as aspirin and allergy remedies, and a broad portfolio of seeds and crop-protection products for agriculture. The group operates globally with a strong presence in Europe, North America and emerging markets.
Where the stock trades today
The Bayer shares (DE000BAY0017) trade on Xetra at 38.60 euros as of 2026-06-23, 17:35, according to Deutsche Börse data.
Key data on the Bayer shares
- Company: Bayer AG
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of 2026-06-23, 17:35): 38.60 EUR
- Market cap: around 38 billion EUR (as of 2026-06-23)
- Sector / industry: Pharmaceuticals / Crop science / Chemicals
- Index membership: DAX, Stoxx Europe 600
- Next earnings date: not officially scheduled
This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities.
